Q3 2023 · 13F-HR
CHI Advisors LLCholdings as filed
Filed 2023-11-13 · accession 0001085146-23-004322
$252.3M
Reported value
28
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $52.3M | 20.7% | 3,014,199 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $35.8M | 14.2% | 2,966,674 | Common | SOLE |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $30.9M | 12.2% | 3,414,189 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $23.0M | 9.12% | 2,262,990 | Common | SOLE |
| 68570P200 | — | ORCHARD THERAPEUTICS PLC | $14.0M | 5.56% | 12,315,654 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $13.5M | 5.35% | 3,414,468 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $13.0M | 5.15% | 407,633 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $9.4M | 3.74% | 2,180,934 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $7.7M | 3.04% | 215,000 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $5.6M | 2.21% | 2,829,712 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $5.4M | 2.14% | 568,379 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $5.3M | 2.11% | 1,270,027 | Common | SOLE |
| 87184Q206 | SYRS | SYROS PHARMACEUTICALS INC | $5.1M | 2.03% | 1,299,359 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $4.7M | 1.85% | 92,888 | Common | SOLE |
| 25460G716 | LABDUSD | DIREXION SHS ETF TR | $4.6M | 1.84% | 225,000 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $3.9M | 1.56% | 1,002,007 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $3.4M | 1.36% | 60,000 | Common | SOLE |
| 690469101 | OVID | OVID THERAPEUTICS INC | $3.3M | 1.32% | 864,822 | Common | SOLE |
| 786700104 | SGMT | SAGIMET BIOSCIENCES INC | $3.1M | 1.22% | 348,842 | Common | SOLE |
| 68217N105 | — | OMEGA THERAPEUTICS INC | $2.3M | 0.90% | 1,055,882 | Common | SOLE |
| 09203E105 | BDTX | BLACK DIAMOND THERAPEUTICS I | $2.1M | 0.82% | 720,000 | Common | SOLE |
| 75120L100 | RLYB | RALLYBIO CORP | $1.3M | 0.52% | 390,734 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $1.2M | 0.47% | 25,000 | Common | SOLE |
| 38870X104 | GRPH | GRAPHITE BIO INC | $572,726 | 0.23% | 230,938 | Common | SOLE |
| 35655L206 | — | FREELINE THERAPEUTICS HLDGS | $372,613 | 0.15% | 86,654 | Common | SOLE |
| 74019P108 | DTIL | PRECISION BIOSCIENCES INC | $207,043 | 0.08% | 606,629 | Common | SOLE |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $157,500 | 0.06% | 50,000 | CALL | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $55,000 | 0.02% | 137,500 | CALL | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.